185 related articles for article (PubMed ID: 23629442)
1. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.
Morita S; Yoshida A; Goto A; Ota S; Tsuta K; Yokozawa K; Asamura H; Nakajima J; Takai D; Mori M; Oka T; Tamaru J; Itoyama S; Furuta K; Fukayama M; Tsuda H
Am J Surg Pathol; 2013 Jun; 37(6):924-32. PubMed ID: 23629442
[TBL] [Abstract][Full Text] [Related]
2. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
Suzuki M; Yazawa T; Ota S; Morimoto J; Yoshino I; Yamanaka S; Inayama Y; Kawabata Y; Shimizu Y; Komatsu M; Notohara K; Koda K; Nakatani Y
Histopathology; 2015 Dec; 67(6):806-16. PubMed ID: 25851923
[TBL] [Abstract][Full Text] [Related]
3. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
[TBL] [Abstract][Full Text] [Related]
5. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
6. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
8. Fetal gut-like differentiation in gallbladder cancer.
Koyama K; Maeda D; Tamura D; Narita C; Kudo-Asabe Y; Sato T; Yamamoto Y; Sageshima M; Nanjo H; Goto A
Hum Pathol; 2017 Dec; 70():27-34. PubMed ID: 28970139
[TBL] [Abstract][Full Text] [Related]
9. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
[TBL] [Abstract][Full Text] [Related]
10. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
11. Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the Lung.
Li Y; Xi SY; Yong JJ; Wu XY; Yang XH; Wang F
Am J Surg Pathol; 2021 Nov; 45(11):1464-1475. PubMed ID: 34138800
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis.
Zhang J; Liang Z; Gao J; Luo Y; Liu T
Histopathology; 2011 Dec; 59(6):1204-14. PubMed ID: 22175900
[TBL] [Abstract][Full Text] [Related]
13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung.
Yousem SA
Hum Pathol; 2013 Nov; 44(11):2467-74. PubMed ID: 24029707
[TBL] [Abstract][Full Text] [Related]
15. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
16. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
17. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
[TBL] [Abstract][Full Text] [Related]
18. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
19. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
20. Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.
Tsuta K; Kawago M; Yoshida A; Sekine S; Asamura H; Furuta K; Kushima R
Lung Cancer; 2014 Jul; 85(1):12-8. PubMed ID: 24768118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
